An Open Label, Randomized, Single Dose, Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of DA 2811 in Healthy Subjects
Latest Information Update: 07 Jun 2022
At a glance
- Drugs Dapagliflozin formate (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Dong-A ST
Most Recent Events
- 02 Jun 2022 Status changed from recruiting to completed.
- 08 Jul 2021 Status changed from not yet recruiting to recruiting.
- 01 Jul 2021 New trial record